September 18, 2017
Direct-acting antiviral therapies Harvoni and Daklinza plus Sovaldi were both safe and highly effective among patients with chronic hepatitis C virus infection who received heart transplants, researchers in Taiwan reported.
“The reported prevalence of HCV infection among heart transplant recipients ranges from 7% to 18%,” Jia-Horng Kao, MD, of the department of internal medicine at National Taiwan University Hospital, Taipei, and colleagues wrote. “The use of [interferon (IFN)-free] direct-acting antiviral agents (DAAs) has confirmed the excellent efficacy and safety for ordinary patients with chronic HCV infection. Till now, there are no case series to evaluate the effectiveness and safety of IFN-free DAAs for heart transplant recipients with chronic HCV infection.”